 |
|
Marijuana and Medicine: Assessing the Science Base
A Summary of the 1999 Institute of Medicine Report
Stanley J. Watson, MD, PhD;
John A. Benson, Jr, MD;
Janet E. Joy, PhD
Arch Gen Psychiatry. 2000;57:547-552.
In response to public pressure to allow the medical use of marijuana, the Office of National Drug Control Policy, Washington, DC, funded a study by the Institute of Medicine evaluating the scientific evidence for benefits and risks of using marijuana as a medicine. The report used scientific reviews, public hearings, and reports from other agencies, and was evaluated by knowledgeable advisors and reviewers. It called for heavier investment in research on the biology of cannabinoid systems, careful clinical studies of cannabinoids in clinical syndromes, analysis of cannabinoids' psychological effects on symptoms, and evaluations of the health consequences of heavy marijuana use; recommends against the use of smoked marijuana in medicine and for the development of a medical cannabinoid inhaler; and recommends that compassionate use of marijuana be considered under carefully reviewed protocols. Finally, the report evaluates the abuse potential, tolerance, withdrawal, and gateway risks of medical use of cannabinoid drugs.
From the Department of Psychiatry, Mental Health Research Institute, University of Michigan, Ann Arbor (Dr Watson); the Oregon Health Sciences University School of Medicine, Portland (Dr Benson); and the Institute of Medicine, Washington, DC (Dr Joy). Dr Benson is dean and professor emeritus of the Oregan Health Sciences University School of Medicine.
THIS ARTICLE HAS BEEN CITED BY OTHER ARTICLES
|
Behavioral Cross-Tolerance between Repeated Intracerebellar Nicotine and Acute {Delta}9-Tetrahydrocannabinol-Induced Cerebellar Ataxia: Role of Cerebellar Nitric Oxide
Smith and Dar
J. Pharmacol. Exp. Ther. 2007;322:243-253.
ABSTRACT
| FULL TEXT
Immunocytochemical Distribution of the Cannabinoid CB1 Receptor in the Primate Neocortex: A Regional and Laminar Analysis
Eggan and Lewis
Cereb Cortex 2007;17:175-191.
ABSTRACT
| FULL TEXT
{Delta}9-Tetrahydrocannabinol-Induced Apoptosis in Jurkat Leukemia T Cells Is Regulated by Translocation of Bad to Mitochondria
Jia et al.
Mol Cancer Res 2006;4:549-562.
ABSTRACT
| FULL TEXT
{Delta}-9-Tetrahydrocannabinol Enhances Breast Cancer Growth and Metastasis by Suppression of the Antitumor Immune Response
McKallip et al.
J. Immunol. 2005;174:3281-3289.
ABSTRACT
| FULL TEXT
Cannabinoid hyperemesis: cyclical hyperemesis in association with chronic cannabis abuse
Allen et al.
Gut 2004;53:1566-1570.
ABSTRACT
| FULL TEXT
Win 55212-2, a cannabinoid receptor agonist, attenuates leukocyte/endothelial interactions in an experimental autoimmune encephalomyelitis model
Ni et al.
Mult Scler 2004;10:158-164.
ABSTRACT
Nonpsychotropic Cannabinoid Receptors Regulate Microglial Cell Migration
Walter et al.
J. Neurosci. 2003;23:1398-1405.
ABSTRACT
| FULL TEXT
Managing Nausea and Vomiting: Current Strategies
Garrett et al.
Crit Care Nurse 2003;23:31-50.
FULL TEXT
Delta 9-Tetrahydrocannabinol-Induced Apoptosis in the Thymus and Spleen as a Mechanism of Immunosuppression in Vitro and in Vivo
McKallip et al.
J. Pharmacol. Exp. Ther. 2002;302:451-465.
ABSTRACT
| FULL TEXT
Targeting CB2 cannabinoid receptors as a novel therapy to treat malignant lymphoblastic disease
McKallip et al.
Blood 2002;100:627-634.
ABSTRACT
| FULL TEXT
Cognitive Functioning of Long-term Heavy Cannabis Users Seeking Treatment
Solowij et al.
JAMA 2002;287:1123-1131.
ABSTRACT
| FULL TEXT
Absence of Delta -9-Tetrahydrocannabinol Dysphoric Effects in Dynorphin-Deficient Mice
Zimmer et al.
J. Neurosci. 2001;21:9499-9505.
ABSTRACT
| FULL TEXT
|
